Showing results (121-130 of 425) with videos related to
Sort By:
Pageof 43
Blood Advances|April 29, 2022
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapyMax Yano, Chia Sharpe, J Rachel Lance, et al.Journal for Immunotherapy of Cancer|September 10, 2025
Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancerZhixin Li, Ningyuan Liu, Zahir Shah, et al.Leukemia & Lymphoma|July 4, 2015
Tocilizumab for steroid refractory acute graft-versus-host diseaseJulianna V F Roddy, Bradley M Haverkos, Ali McBride, et al.Investigational New Drugs|May 19, 2019
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AMLJae Yoon Jeon, Qiuhong Zhao, Daelynn R Buelow, et al.Blood|December 16, 2010
The PP2A inhibitor SET regulates granzyme B expression in human natural killer cellsRossana Trotta, David Ciarlariello, Jessica Dal Col, et al.Blood|February 27, 2009
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22Tiffany Hughes, Brian Becknell, Susan McClory, et al.The Journal of Allergy and Clinical Immunology|July 3, 2007
Chronic lymphocytosis of functionally immature natural killer cellsAnthony R French, Sungjin Kim, Todd A Fehniger, et al.Cancers|November 26, 2022
Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional ExperienceJustin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.Leukemia & Lymphoma|September 24, 2019
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 studyBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.Bone Marrow Transplantation|February 16, 2018
Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipientsDaniel R Richardson, Ying Huang, Heather L McGinty, et al.Pageof 43